CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical and non-clinical data on BTK inhibitor BRUKINSA™

(zanubrutinib) and clinical data on anti-PD-1 antibody tislelizumab will be presented in an oral presentation and eight posters at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14, 2020.